Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD8205 · 1 trial · 5 indications
Number of patients with adverse events by system organ class and preferred term
Number of patients with serious adverse events by system organ class and preferred term
A DLT is defined as any toxicity that occurs from the first dose of study treatment up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation and which includes pre-defined haematological and non-haematological toxicities.
Description of laboratory findings and vital signs variables over time including change from baseline.
| Arm | Type | Description |
|---|---|---|
| Sub-Study 1 AZD8205 Monotherapy | EXPERIMENTAL | Sub-Study 1 has two parts: Part A : The aim is to determine the safety, tolerability, Recommended Phase 2 Dose (RP2D), and/or the Maximum Tolerated Dose (MTD) of AZD8205. Part B: The aim of dose expansion is to evaluate anti-tumor activity of AZD8205 as monotherapy in select solid tumors. |
| Sub Study 2: AZD8205 in combination with rilvegostomig | EXPERIMENTAL | Sub-Study 2 has two parts: Part A : Dose escalation to determine the safety, tolerability of AZD8205 + rilvegostomig Part B: Dose expansion to evaluate anti-tumor activity of AZD8205 + rilvegostomig in select solid tumors. |
| Sub-Study 3 AZD8205 in combination with saruparib, with or without rilvegostomig | EXPERIMENTAL | Sub-Study 3 has two parts: Part A : Dose escalation to determine the safety, tolerability of AZD8205 + saruparib. Rilvegostomig may be added in a triplet combination once an AZD8205 + saruparib combination dose/schedule has been considered safe. Part B: Dose expansion to evaluate anti-tumor activity of AZD8205 + saruparib with or without rilvegostomig in select solid tumors. |
| Sub-Study 4: AZD8205 in combination with AZD9574 with or without rilvegostomig (AZD2936) | EXPERIMENTAL | Sub-Study 4 has two parts: Part A : Dose escalation to determine the safety, tolerability of AZD8205 + AZD9574. Rilvegostomig may be added in a triplet combination once an AZD8205 + AZD9574 combination dose/schedule has been considered safe. Part B: may be added in the future depending on emerging data, following a formal protocol amendment. |
| Name | Type | Description |
|---|---|---|
| AZD8205 | DRUG | AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers. |
| AZD8205 and AZD2936 (Rilvegostomig) | DRUG | AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial cancers and squamous non-small cell lung cancers. Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors. |
| AZD8205 and AZD5305 (saruparib) | DRUG | AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors. |
| AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig) | DRUG | AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. Saruparib is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors. Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors. |
| AZD8205 in combination with AZD9574 | DRUG | AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. AZD9574 is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors. |
| AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936) | DRUG | AZD8205 is an antibody drug conjugate that has the potential to treat a wide variety of solid tumors including but not limited to breast cancer, Biliary Tract Cancer, ovarian, endometrial and squamous non-small cell lung cancers. AZD9574 is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells, resulting in cell death, and is a potential anticancer therapy in patients with advanced or metastatic solid tumors. Rilvegostomig is a bispecific antibody that specifically binds to human TIGIT and PD-1 and is a potential anticancer therapy in patients with advanced or metastatic solid tumors. |
Key Inclusion Criteria: * Age ≥ 18 years * Relapsed/metastatic solid tumors treated with prior adequate standard of care therapy for tumor type and stage of disease or where in the opinion of the Investigator, a clinical trial is the best option for the next treatment based on response and/or toler...
Top 20 of 92 competitors
AZD8205 is an investigational small molecule being studied for the treatment of breast cancer. It is currently in Phase 1 clinical development, with a trial enrolling participants with advanced or metastatic solid malignancies, including breast cancer. The drug is being evaluated alone or in combination, and is not yet approved by regulatory authorities.
AZD8205 is a small molecule being developed by AstraZeneca. Its specific molecular target has not been disclosed in the available information. The drug is being investigated for its potential in treating advanced or metastatic solid tumors, including breast cancer, but its mechanism of action is not publicly detailed.
AZD8205 is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in Phase 1 clinical trials, and AstraZeneca is responsible for its research and development.
AZD8205 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or any other regulatory body. The ongoing Phase 1 trial is recruiting participants to evaluate the drug's safety, tolerability, and preliminary efficacy in advanced or metastatic solid tumors.
AZD8205 is being studied in a single clinical trial registered as NCT05123482. This is a Phase I/IIa study of AZD8205 given alone or combined, in participants with advanced or metastatic solid malignancies. The trial is currently recruiting and has an estimated enrollment of 460 participants across multiple countries.
AZD8205 is a distinct investigational compound developed by AstraZeneca. No alternative names or aliases for AZD8205 have been reported in the available clinical trial information. It is being studied under its unique identifier in a Phase 1 clinical trial for advanced solid tumors.